Results of experimental studies have shown that intramyocardial implantation of bone marrow
cells induces neovascularisation and improves heart function after myocardial infarction. …

Background Patient outcomes are poor for aggressive B-cell non-Hodgkin’s lymphomas not
responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an …

Diffuse large B cell lymphoma (DLBCL) is the most common form of blood cancer and is
characterized by a striking degree of genetic and clinical heterogeneity. This heterogeneity …

Purpose To explore a more effective treatment for newly diagnosed stage IV, relapsed, or
refractory extranodal natural killer/T-cell lymphoma, nasal type (ENKL), we conducted a phase …

Background & Aims: De novo hepatitis B virus (HBV)-related hepatitis after chemotherapy
results in high morbidity and mortality. We evaluate the clinical course of de novo HBV-related …

Nasal natural killer (NK) cell lymphoma is rare, so that its optimal therapy, long-term
outcome, and prognostic factors are unclear. Data on 52 men and 15 women with well-characterized …

Natural killer (NK)/T-cell lymphomas failing L-asparaginse regimens have no known salvage
and are almost invariably fatal. Seven male patients with NK/T-cell lymphoma (median age, …

Natural killer/T-cell lymphoma is rare and aggressive, with poor outcome. Optimal treatment
remains unclear. A novel regimen dexamethasone, methotrexate, ifosfamide, l-asparaginase…

Purpose Patterns of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg)
–negative, antihepatitis B core antigen antibody (anti-HBc) –positive patients with …

Patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous
leukemia (CML-AP) have very limited therapeutic options. Nilotinib is a highly selective BCR-ABL …